The heart is the first organ to develop during embryogenesis 1 . The general principles of cardiac 1 9
development have been studied in great detail on a morphological and molecular basis . These 2 0 studies have identified key signaling events and transcription factor networks which are involved 2 1
in the specification and differentiation of cardiac myocytes (CMs) [1] [2] [3] [4] [5] [6] . Many of these transitions 2 2
involve changes of gene expression. This in turn is regulated by epigenetic processes including 2 3
CpG methylation (mCpG) and histone modifications. However, the detailed epigenetic processes 2 4 involved in maturation from fetal to adult CMs and in cardiac disease leading to terminal heart 2 5 failure have not been fully uncovered, yet. 2 6 2 7
Epigenetic studies in human hearts have identified altered mCpG in chronic heart failure 8, 9 . Due 2 8
to technical restrictions, these studies were performed in heart tissue and therefore the affected 2 9
cell type(s) could not be identified. Epigenetic mechanisms are highly cell type-specific requiring 3 0 cell separation techniques to determine epigenomic features in a specific cell type, especially 3 1
when keeping in mind that the cellular composition of the human heart is highly dynamic. 3 2
Previous studies in mice have used enzymatic dissociation by the Langendorff technique 10,11 or 3 3 additional purification of dissociated cardiac cells by flow cytometry 12, 13 to study cell-type specific 3 4
features of the CM transcriptome and epigenome, respectively. Purification of CM nuclei by 3 5 fluorescence-assisted sorting has led to the identification of cell type-specific mCpG and histone 1 modification signatures in CMs during mouse heart development and maturation 12 . Based on 2 this method 14,15 , we used a nuclear staining strategy to isolate CM nuclei from intact pre-and 3 postnatal human heart tissue and subjected these nuclei to comprehensive analysis of the 4 epigenome during prenatal development, postnatal maturation and in heart failure. 5 6
Here, we describe the human CM epigenome during prenatal development and postnatal 7 maturation of the heart from infant to adult age and in terminal failure. During normal life span of 8
CMs gene regulation was mainly orchestrated by dynamic mCpG and canonical histone marks 9
at distal regulatory and genic regions. In contrast to previous findings in heart tissue, expression 1 0
of the pathological gene program in heart failure was not accompanied by changes in the CM 1 1
DNA methylome but by active histone marks. In addition, our study provides the first functional 1 2 map of the non-coding genome of human CMs throughout life. Linking this functional annotation 1 3
with known genetic polymorphisms revealed the presence of cardiovascular disease-associated 1 4
polymorphisms in active CM enhancers. 1 5
RESULTS

2
Flow cytometry and sorting of human CM nuclei 3
To determine the dynamics of the CM epigenome during prenatal development and postnatal 4 maturation as well as in disease, cardiac left ventricular tissue was analyzed at three stages 5 (fetal, 16-23 weeks of pregnancy; infant, 1-12 months of age; adult, 46-60 years) and at one 6 disease condition of end stage heart failure (56-63 years, LV ejection fraction 19 ± 2%, Tab. S1). 7
Fluorescence-activated sorting of cardiac nuclei was applied to ensure CM-specificity ( Fig. 1a ). 8
Antibodies raised against pericentriolar material 1 (PCM1) or signal regulatory protein alpha 9
(SIRPA) were used to stain postnatal CM nuclei and fetal CMs, respectively 12,15,16 . These 1 0 markers are highly specific for postnatal and fetal CMs, respectively 12, 15, 16 . In addition, we 1 1
identified and validated phospholamban (PLN) as a specific marker for prenatal and postnatal 1 2 CM nuclei. In the heart, only CMs show high abundance and strong nuclear localization of 1 3 PLN 17,18 . We confirmed the validity of nuclear PLN using dual labeling of CM nuclei with PCM1 1 4
by flow cytometry (Fig. 1b, Supplementary Fig. 1,2 ). Fetal and infantile hearts contained a higher 1 5
percentage of CM nuclei than adult hearts (Fig. 1c) . Notably, adult CM nuclei showed a higher 1 6 degree of ploidy than fetal and infantile CM nuclei ( Fig. 1d ). While fetal and infantile hearts 1 7
mostly contained diploid CM nuclei, the percentage of tetraploid nuclei increased significantly 1 8
until adulthood ( Fig. 1d ). Adult failing myocytes showed even a higher proportion of polyploid 1 9 nuclei ( Fig. 1d ). 2 0 2 1
CMs were isolated with high purity (≥ 98%) from LV tissue ( Fig. 1e , Supplementary Fig. 2 ).
Purified nuclei were processed to generate high-coverage DNA methylomes (WGBS), 5-2 3 hydroxymethylomes (5hmC-seq), profiles of seven histone marks (ChIP-seq) and nuclear gene 2 4 expression (RNA-seq). All data sets were derived from independent biological replicates 2 5
( Supplementary Table 2 ). For nine patients, at least six histone marks, mCpG and nuclear RNA 2 6 expression were generated from the same samples (Supplementary Table 2 ). As 5hmC-seq 2 7 required higher amount of input DNA, different biological replicates were pooled (Supplementary 2 8 Table 2 ). In total, we generated more than 3 billion mapped ChIP-seq and 60 million 5hmC-seq 2 9
reads as well as 1 billion mapped RNA-seq fragments. The cumulative CpG coverage resulting 3 0 from whole-genome bisulfite sequencing was 135-fold (Supplementary Table 2 ). Data generated 3 1 from independent biological replicates yielded highly correlating values for ChIP-seq 3 2 ( Supplementary Fig. 3 ), RNA-seq ( Supplementary Fig. 4a ) and for mCpG ( Supplementary Fig.  3 3 5). Sequencing data further confirmed the validity of the FACS sorting strategy for CM nuclei. 3 4
CpG methylation data from SIRPA-sorted cells correlated highly with data obtained from 3 5 PCM1/PLN-sorted nuclei ( Supplementary Fig. 5 , correlation coefficient ≥ 0.95). Sequencing of 1 nuclear RNA showed expression of CM genes in PLN-and PCM1-positive nuclei and no 2 expression of non-CM genes ( Supplementary Fig. 6a ). RNA-profiles of PCM1-and PLN-sorted 3 were highly correlated (R 2 = 0.96, Supplementary Fig. 6b ). 4 5
Representative traces show a genomic region containing troponin T2 (TNNT2) and troponin I1 6 (TNNI1, Fig. 1f ). TNNT2 is highly expressed in CMs from fetal to adult stages and shows 7 sequential loss of genic mCpG and a promoter enrichment of H3K27ac, H3K9ac and H3K4me3 8 and genic enrichment of H3K36me3 (Fig. 1f ). The fetally expressed TNNI1 gene was silenced 9 postnatally, coinciding with genic de novo mCpG loss and loss of active histone marks H3K27ac, 1 0
H3K9ac, H3K4me3 and H3K36me3 (Fig. 1f ). Several regions with distal regulatory domain 1 1 signatures, including low mCpG and enrichment of H3K4me1, were identified. While most of 1 2
these regions seem to be relatively stable at this genomic locus, dynamic establishment of a 1 3 distal regulatory signature occurred during CM development in an intronic region of the 1 4 plakophilin (PKP1) gene ( Fig. 1f ). 1 5 1 6
Next, epigenetic signatures of heart tissue 19-21 and CM were compared to get insight into cell 1 7
type-specificity ( Supplementary Fig. 7 ). Loci containing the CM-specific myosin heavy chain α 1 8
and β genes as well as the fibroblast gene biglycan 22 or the endothelial gene VE-cadherin 1 9
revealed distinct differences in mCpG and chromatin state between tissue and CMs 2 0
( Supplementary Fig. 7b-d ). Genes which were hypomethylated in CMs versus heart tissue 2 1
( Supplementary Fig. 7e , group 1) were involved in cardiac muscle function ( Supplementary Fig.  2  2 7f, group 1). In contrast, genes with higher levels of mCpG in myocytes versus heart tissue, 2 3
represented developmental processes of the cardiovascular system, vasculature and connective 2 4 tissue ( Supplementary Fig. 7e , f, group 2). Elevated mCpG was also observed in promoter 2 5 regions flanking the transcription start site ( Supplementary Fig. 7g ). 2 6 2 7
Systematic analysis of CM and VISTA heart enhancers 23 revealed an overlap of 49% 2 8
( Supplementary Fig. 7h ). VISTA enhancers not present in CMs were adjacent to genes involved 2 9
in artery morphogenesis and collagen fibril organization while CM-specific ones were adjacent to 3 0 genes related to cardiac muscle contraction and morphogenesis ( Supplementary Fig. 7i , j). 3 1
Narrowing the list of VISTA heart enhancers down to those with confirmed function in mouse 3 2 embryonic hearts in vivo 23 showed a 90% overlap with CM enhancers ( Supplementary Fig. 7k ). 3 3 3 4 mCpG-guided annotation of genomic elements 3 5
Genomic regions, including distal regulatory domains and genic regions, show distinct mCpG 1 patterns. Therefore, we segmented the genome into partially methylated, unmethylated and low 2 methylated regions (PMR, UMR, LMR) 24,25 . We identified large PMRs with highly disordered 3 mCpG covering 43% of the genome ( Supplementary Fig. 8 , Supplementary Fig. 9a ). PMRs 4 spanning large genomic domains have been observed in other somatic cell types 26 , too, but 5
were not detectable in mCpG data obtained from human heart tissues 19 . In agreement with 6 previous studies 27 , most CM PMRs ( Supplementary Fig. 10a ) showed low levels of active 7 histone marks ( Supplementary Fig. 10b -d) and are associated with a silent chromatin state 8
( Supplementary Fig. 11a , b). 9 1 0
Further segmentation of mCpG data resulted in UMRs and LMRs which covered 3% of the 1 1 genome, each ( Supplementary Fig. 9a ). LMRs ( Supplementary Fig. 10e -h) showed enrichment 1 2
for H3K4me1 ( Supplementary Fig. 10g ), depletion of H3K4me3 ( Supplementary Fig. 10h ) and 1 3
were associated with an enhancer-associated chromatin state ( Supplementary Fig. 11a , b). 1 4
Overall, 73-78% of LMRs showed an enhancer chromatin signature ( Supplementary Fig. 11d ) 1 5
and 55% overlap with strong enhancers ( Supplementary Fig. 11e ). Genes adjacent to LMRs with 1 6 enhancer chromatin signature were significantly higher expressed as genes neighboring LMRs 1 7
with non-enhancer chromatin state ( Supplementary Fig. 11e ). LMRs were strongly enriched for 1 8 transcription factor motifs ( Supplementary Fig. 10m ) and were predominantly found in intronic 1 9
and intergenic regions ( Supplementary Fig. 10n ). The five most significantly enriched motifs 2 0 contained binding sites for the CCCTC-binding factor (CTCF) and transcription factors of the 2 1 myocyte enhancer factor-2 (MEF2), GATA, TGGCA-binding protein (CTF/NF1) and T-box 2 2 families ( Supplementary Fig. 10m ). 2 3 2 4
Compared to LMRs, UMRs were larger in size ( Supplementary Fig. 10i vs. e), showed 2 5 enrichment of the promoter mark H3K4me3 ( Supplementary Fig. 10l ) and predominantly 2 6
spanned genic regions and annotated CpG islands ( Supplementary Fig. 10n , o). To specifically 2 7
analyze characteristics of genes with low methylated gene bodies we annotated genic UMRs 2 8
(gUMR). They span genic parts overlapping with transcription start sites. To eliminate a potential 2 9
bias, regions overlapping with CpG islands were excluded from gUMR annotation ( Fig. 1f , 3 0 Supplementary Fig. 10o ). 3 1 3 2
Genic unmethylated regions in CMs 3 3
Next, we analyzed the correlation of gene expression with inheritable marks ( Fig. 2a , 3 4 Supplementary Fig. 12 ). Ranking of genes according to their gene expression level revealed an 3 5 inverse correlation of mCpG and gene expression around the transcription start site (TSS) ( Fig.  1 2a, Supplementary Fig. 12 ). Analysis of histone modifications showed a positive correlation of 2 active histone marks (H3K27ac, H3K9ac, H3K36me3, H3K4me1, H3K4me3) with gene 3 expression, while genes with very low transcriptional activity (<1 FPKM) were decorated with the 4 inactive marks H3K27me3 and H3K9me3 ( Fig. 2a , Supplementary Fig. 12 ). Comparing genes 5 expressed (≥1 FPKM) in at least one of the assessed stages (6,515 genes, Fig. 2a ) revealed 6 that 45% were expressed independent of age or disease. The largest number of genes with 7 stage-specific expression was detected in fetal CMs (>16%, Supplementary Fig. 4b ). These 8 genes were significantly associated with cell cycle and chromatin organization (Supplementary 9 Fig. 4b ). 1 0
The marked CpG demethylation of genic regions encouraged us to characterize genes with 1 2 extended genic CpG demethylation. We identified 996 genes with a gUMR covering more than 1 3 25% or at least 5kb of the gene ( Fig. 2b , Supplementary Table 3 ). The majority of these genes 1 4
were marked with active histone modifications including H3K27ac and were depleted for the 1 5
polycomb mark H3K27me3 ( Fig. 2b , Supplementary Fig. 13 , group I). They showed a 1 6
characteristic mCpG pattern with regions of low mCpG overlapping with the transcription start 1 7 site and progressing towards the 3' end of the gene ( Fig. 2b , Supplementary Fig. 13b , group I). 1 8
These genes showed high transcriptional activity ( Fig. 2b , Supplementary Fig. 13a , group I) and 1 9
include myofibril proteins or are known to be implicated in muscle structure development and 2 0 muscle structure system processes ( Fig. 2b , group I, Supplementary Table 3 ). 2 1 2 2
The remaining subset of genes ( Fig. 2b , group II) showed the typical signature of inactive 2 3 chromatin, including enrichment of H3K27me3 ( Fig. 2b , Supplementary Fig. 13i , j, group II) and 2 4 depletion of active histone marks ( Fig. 2b , Supplementary Fig. 13d -f, h, group II). This group of 2 5 genes showed stable low mCpG and no significant transcriptional activity ( Fig. 2b , 2 6 Supplementary Fig. 13a , group II). These genes were associated with DNA binding and pattern 2 7 specification ( Fig. 2b , group II, Supplementary Table 3 ). 2 8 2 9
Dynamic gUMR mCpG in CMs 3 0
To characterize the dynamics of genic mCpG during cardiac maturation from fetal until adult 3 1 stages and in disease, all 14,688 genes harboring a gUMR were analyzed. From fetal life until 3 2 adulthood, 529 genes exhibited differential gUMR mCpG (DM-gUMRs) ( Fig. 2c ). This affected 3 3 more than 16,000 CpGs ( Supplementary Fig. 9e ). Loss of mCpG in DM-gUMRs was associated 3 4
with increased expression of genes essential for myofibril and sarcomere structures as well as 3 5 regulation of contraction ( Fig. 2d, group 1) . In contrast, a developmental increase of mCpG in 1 DM-gUMRs was linked to decreased gene expression and affected primarily developmental 2 genes ( Fig. 2d , group 2). Changes in genic mCpG were accompanied by concordant changes of 3 histone marks ( Fig. 2e ). Demethylated genic regions during maturation gained the active histone 4 marks H3K27ac, H3K9ac, H3K36me3 and H3K4me3 ( Fig. 2e ). In contrast, hypermethylated 5
regions showed a loss of these marks ( Fig. 2e ). This illustrates the tight link of genic mCpG and 6 histone marks with gene expression during myocyte development and postnatal maturation. 7 8
Development versus maturation of gUMR mCpG 9
We separately analyzed gUMR mCpG during prenatal development and postnatal maturation 1 0
( Supplementary Fig. 14) . We found 29 gUMRs which were hypomethylated and 12 gUMRs 1 1
which were hypermethylated from fetal to infant stage ( Supplementary Fig. 14a , group I, II). 1 2
Postnatally, 188 gUMRs were further demethylated and 34 gUMRs were hypermethylated 1 3
( Supplementary Fig. 14a , group III, IV). 59% of genes which were differentially methylated 1 4
prenatally showed continuing methylation changes postnatally. No genes with opposing mCpG 1 5
changes during pre-versus postnatal life were identified. We further performed a genome-wide 1 6
PCA analysis of genic mCpG. This resulted in a trajectory from prenatal development to 1 7 postnatal maturation ( Supplementary Fig. 15a ). Comparable trajectories were observed for gene 1 8
expression and histone modifications ( Supplementary Fig. 15b -i). Thus, mCpG developed 1 9
continuously from prenatal to postnatal life. 2 0 2 1 gUMR mCpG is stable in chronic heart failure 2 2
Remarkably, only 6 out of 14,688 gUMR genes were significantly altered (DM-gUMRs) in adult 2 3
failing versus non-failing CMs ( Supplementary Fig. 16 ). These differences were not 2 4
accompanied by consistent alterations in gene expression ( Supplementary Fig. 16 ). 2 5 2 6
Epigenetic signature of disease-associated gene expression 2 7
Since we could not identify a clear link between DM-gUMRs and RNA expression, we analyzed 2 8 epigenetic signatures of differentially expressed genes in failing versus non-failing adult CM 2 9 nuclei ( Fig. 3 ). For several pathologically relevant genes, including connective tissue growth 3 0 factor (CTGF) and natriuretic peptides A and B (NPPA, NPPB), we identified concordant 3 1 changes in active histone marks (H3K27ac, H3K4me3, H3K9ac and H3K36me3) and gene 3 2 expression in failing CMs (Fig. 3a) . However, these genes did not show overt alterations in 3 3 promoter or gene body mCpG ( Fig. 3a ).
4 5
To assess this on a genome-wide scale, we ranked all differentially expressed genes in failing 1 CM nuclei according to the magnitude of disease-associated changes in expression ( Fig. 3b ).
2
Changes in gene expression were accompanied by concordant alterations in active histone 3 marks. The best predictive marks for gene expression were H3K27ac and H3K36me3 4 ( Supplementary Fig. 17a , c). In combination, these marks explained 50% of the gene expression 5 rank (Fig. 3b , R 2 = 0.509). For other histone modifications as well as for mCpG in gUMRs 6 ( Supplementary Fig. 17 ) and genic regions ( Fig. 3b ) we did not observe R 2 values exceeding 7 0.14. This suggest that disease-associated changes in gene expression primarily involve 8 remodeling of distinct active histone modifications, while especially repressive marks remain 9 relatively stable. 1 0
Reconfiguration of distal regulatory domain mCpG 1 2
Segmentation of mCpG data identified more than 100,000 LMRs with distal regulatory properties 1 3
( Fig. 4a , Supplementary Fig. 9c , Supplementary Fig. 10e -h, Supplementary Fig. 11b ). Of these 1 4
regions, 18% ( Fig. 4a , groups I + III, Supplementary Table 4 ) were differentially methylated (DM-1 5 LMR) between fetal and adult stages. The main fraction (77%) of DM-LMRs showed a 1 6
developmental loss of mCpG ( Fig. 4 , group I) and was strongly enriched for transcription factor 1 7
binding motifs for CTF/NF1 and MEF2 (Fig. 4b) . These DM-LMRs were located next to genes 1 8 essential for cardiac contraction and energy supply ( Fig. 4c ). In contrast, DM-LMRs with 1 9
increasing mCpG in adult vs. fetal CMs (Fig. 4a , group III) were enriched for DNA sequences 2 0 similar to known motifs of GATA, TEAD and T-box transcription factors (Fig. 4d ). These DM-2 1
LMRs were adjacent to genes involved in general and muscle-specific early developmental and 2 2 differentiation processes ( Fig. 4e ). 2 3 2 4
Loss of mCpG in DM-LMRs was accompanied by an increase of the active histone marks 2 5
H3K27ac and H3K4me1 and a concordant decrease of H3K27me3 enrichment (Fig. 4f , group I).
6
These DM-LMRs were associated with neighboring genes that lost gUMR methylation and 2 7
showed increased expression ( Fig. 4g ,h, group I). CpG demethylation of these DM-LMRs was 2 8
preceded by establishment of 5hmC at the center of the nascent LMRs indicating an active TET-2 9 dependent demethylation ( Fig. 4f , group I). LMRs with stable mCpG showed a relatively 3 0 constant level of histone marks, gene expression of neighboring genes and their gUMR mCpG 3 1
( Fig. 4f -h, groups II). LMR-DMRs with increased mCpG from the fetal to the adult stage 3 2 contained a primarily inactive histone signature as illustrated by high H3K27me3 and low 3 3
H3K4me1 as well as H3K27ac signals (Fig. 4f , group III). Neighboring genes showed an 3 4 increase in genic mCpG and a decrease in gene expression ( Fig. 4g , h, group III). This 3 5 demonstrates an interplay of mCpG and histone marks at regulatory domains and their influence 1 on transcriptional activity during development and maturation of CMs. 2 3
Development versus maturation of mCpG of LMRs 4
Comparing LMRs during prenatal development and postnatal maturation indicated that loss of 5 mCpG prevails in postnatal CMs (7,160 hypo-vs. 693 hyper-methylated DM-LMRs, 6 Supplementary Fig. 14b ). During development the number of DM-LMRs with loss or gain of 7 mCpG were comparable ( Supplementary Fig. 14b ). We found a similar set of transcription factor 8 motifs to be enriched in DM-LMRs during the prenatal and postnatal periods (Supplementary 9 Fig. 14c ). Comparing development and maturation only 0.36% (35) of DM-LMRs showed 1 0
opposing mCpG (not shown). 1 1 1 2
Low methylated regions in heart failure 1 3
Next, we analyzed DM-LMRs of adult failing versus non-failing CM nuclei ( Fig. 5 ). Heart failure 1 4
affected the mCpG levels of 3,647 CpGs within 366 DM-LMRs ( Fig. 5a , Supplementary Fig. 9c ). 1 5
The extent of mCpG changes was more than 45-fold smaller in disease as compared to 1 6 development (176,630 CpGs within 18,095 DM-LMRs) ( Supplementary Fig. 9c ). 1 7 1 8
DM-LMRs with a disease-associated loss of mCpG showed a tendency for higher levels of 1 9
H3K27ac and H3K4me1 (Fig. 5b , c, group I). These DM-LMRs were enriched for sequences 2 0 similar to the transcription factor motif of CTF/NF1 ( Fig. 5d , group I). Genes adjacent to these 2 1 DM-LMRs showed stable genic mCpG ( Fig. 5e , group I) and gene expression ( Fig. 5f , group I). 2 2 GREAT analysis 28 of these genes did not reveal an association with cardiac gene programs. We 2 3
identified 85 DM-LMRs with increasing mCpG in adult failing as compared with non-failing CMs 2 4 ( Fig. 5a , b, group II). These DM-LMRs did not show changes of active histone marks ( Fig. 5c , 2 5 group II), gUMR mCpG or gene expression of adjacent genes (Fig. 5e, f ). This indicates, that 2 6 disease-associated alterations omCpG are rare and not directly linked to alterations of other 2 7
inheritable marks or gene expression. 2 8 2 9
Enrichment of genetic variants in low methylated regions 3 0
Cardiac cis-regulatory regions contain disease-associated single nucleotide polymorphisms 3 1
(SNPs) 29 . To test whether genetic variations map to LMRs in CMs, we analyzed SNPs linked 3 2 with different disease traits. SNPs associated with cardiac arrhythmia or coronary heart disease 3 3
were most significantly enriched in CM LMRs (Fig. 6a ). SNPs associated with congenital heart 3 4 disease were also enriched in LMRs, but this association did not reach statistical significance 3 5 ( Fig. 6a ). SNPs associated with diseases in other organ systems showed smaller or no 1 enrichment in CM LMRs (Fig. 6a ). LMRs associated with disease SNPs showed a very low 2 overlap between cardiac arrhythmia, coronary heart disease and non-cardiovascular disease, 3 respectively ( Fig. 6b ). GREAT analysis identified that LMR regions associated with cardiac 4 arrhythmia were enriched for genes involved in cardiac excitation and conduction or cardiac 5 contraction (Fig. 6c ). Disease-associated LMRs showed characteristics of cis-regulatory regions, 6
including enrichment of H3K4me1 and H3K27ac (Fig. 6d, e ). These regions showed increasing 7
H3K27ac levels ( Fig. 6e ) and a significant loss of mCpG ( Fig. 6f ) from fetal to adult stages. This 8
indicates that genetic polymorphisms that are linked with cardiac disease traits are enriched in 9
cis-regulatory regions of CMs. 1 0
Here, we present epigenome maps of human cardiac myocytes (CM) during prenatal 3 development, postnatal maturation and in chronic heart failure. Our data reveal a highly dynamic 4
interplay between mCpG and histone modification to shape the CM transcriptome during 5 development and maturation (Fig. 7) . In chronic heart failure, mCpG of genic and cis-regulatory 6 regions was remarkably stable. Pathological gene expression was accompanied by changes of 7 active histone marks (Fig. 7) . Furthermore, the significant enrichment of genetic polymorphisms 8 that have been linked with cardiac disease underlines the pathological relevance of active cis-9 regulatory elements in CMs (Fig. 7 ). 1 0
Several studies highlight the importance of cell type-specific epigenomic analyses 30 . However, 1 2
isolation of cardiac myocytes from human hearts is challenging. In 2009, Bergmann et al. 1  3 described a technique to isolate CM nuclei using specific protein markers, including 1 4 pericentriolar material 1 (PCM1), to study CM proliferation in human hearts 14, 15 . The specificity of 1 5
PCM1 to label postnatal CM nuclei has been characterized extensively for mouse and human 1 6
hearts 12,13,15 . SIRPA has been used previously as a marker of fetal CMs 16 . Here we provide a 1 7
common marker for both, prenatal and postnatal CM nuclei, phospholamban (PLN). The 1 8
specificity and validity of PLN is strongly supported by immunohistochemical staining 17 and by 1 9
experimental evidence provided in the present study. Labeling of cardiac nuclei with anti-PLN 2 0
antibodies enables identification and purification of CM nuclei from pre-and postnatal human 2 1 hearts. 2 2 2 3
Our genome-wide analysis of mCpG identified genic regions with unmethylated CpGs 2 4 (gUMR) 22,23,33 . In concordance with previous studies 12,31,32 , depletion of mCpG affected 2 5 transcribed regions extending from the transcription start site towards the 5' end of genes. Low 2 6 levels of mCpG correlated with higher levels of active histone marks and gene expression. 2 7
Analysis of fetal, infantile and adult non-failing datasets revealed dynamic genic mCpG during 2 8
pre-and postnatal development affecting 10% of all genes harboring a gUMR. Alterations within 2 9
these genes were also present on the layer of histone modifications and gene expression and 3 0 affect especially genes involved in the maturation of CMs. 3 1 3 2
Notably, the negative correlation between mCpG and gene expression was not observed for a 3 3 large group of early developmental genes that were marked with H3K27me3. These genes 3 4
showed low mCpG despite very low transcriptional activity. Intriguingly, low mCpG was not 3 5 restricted to genic regions for these genes but extended into surrounding genomic regions, 1
which have previously been termed mCpG valleys 33 . 2 3
Recent studies show that regions with low mCpG (LMR) have cis-regulatory properties 24,25,34,35 . 4
In myocyte nuclei, we identified more than 100,000 LMRs. The high degree of cell type 5 specificity of cis-regulatory domains with low mCpG is underlined by the strong enrichment of 6 cardiac transcription factor motifs within these regions. Notably, motifs of different transcription 7 factors were clustered within most cis-regulatory regions. The most prevalent combinations 8
include T-box, GATA or MEF2 motifs. Co-occupancy of these and other cardiac transcription 9
factors has been described previously using a murine atrial cardiac muscle cell line 36 or silent/repressive elements. We found a large overlap between cis-regulatory regions identified 1 4
as LMRs and enhancers predicted by chromatin marks. 1 5 1 6
These findings supports, that localized low mCpG is a hallmark of cis-regulatory regions 24,25,34,38 . 1 7
Establishment of LMRs has been shown to depend on transcription factor occupancy 25,39 . LMRs 1 8
show lowest mCpG values at accessible sites as revealed by parallel analysis of mCpG and 1 9
accessibility in single cells 34, 40 . Cis-regulatory sites marked by low mCpG can act as enhancers 2 0 or silencers (Fig. 1f , grey highlighted LMRs). Chromatin state annotation using histone marks is 2 1
important for the identification of the activation state. Chromatin modifications are deposited at 2 2 histones flanking transcription factor binding sites 41 . Combining ChIP-seq and WGBS will likely 2 3
improve the prediction of localization and activation state of cis-regulatory regions. A recent 2 4 study invented an algorithm integrating ChIP-seq and WGBS data for prediction of tissue-2 5 specific enhancers 35 . 2 6 2 7
Comparing our data with a recent study reporting >80,000 putative enhancers (264 Mb) in 2 8 mouse and human pre-and postnatal hearts 23 revealed that 17% of enhancers detected in 2 9
hearts do not overlap with enhancers detected in CM. These "heart-specific" enhancers were 3 0 situated near genes associated with non-CM functions. Looking at in vivo confirmed VISTA heart 3 1 enhancers 23 the overlap with CM enhancers is 90%. Thus, our study provides a comprehensive 3 2 annotation and characterization of cis-regulatory regions in human cardiac myocytes. 3 3 3 4
During prenatal development and postnatal maturation over 18% of CM cis-regulatory regions 1 identified as LMRs showed differential mCpG. Concordant gene expression and gUMR mCpG 2 changes of adjacent genes suggest the functional relevance of these cis-regulatory sites. 3
Affected genes were implicated in development and maturation of CMs highlighting the 4 biological relevance of these observations. Regions gaining mCpG showed significant 5 enrichment of motifs related to the GATA, T-box and TEAD families. A similar combination of 6 motifs has previously been found in murine HL-1 cells 36 . In contrast, loss of mCpG affected 7 regions containing MEF2 and CTF/NF1 motifs. mCpG changes were associated with concordant 8 changes in histone modifications. Notably, regions gaining mCpG during development already 9
showed low levels of enhancer marks at the fetal stage. This may indicate that changes at the 1 0 chromatin level precede altered mCpG. These differences in kinetics of histone modifications 1 1 and mCpG have previously been observed during mouse organ development and were termed 1 2 "epigenetic memory" 42 . In addition, regions losing mCpG were pre-marked with 5hmC, 1 3
indicating active CpG demethylation 43 . These results clearly show that developmental mCpG of 1 4
cis-regulatory sites is actively modified after lineage decision and orchestrates with dynamic 1 5 modification of histones and gene expression. 1 6 1 7
Comparison of mCpG changes during development of fetal and maturation of infantile CMs 1 8
revealed mCpG continuum with predominant loss of mCpG. In contrast, a recent study 44 1 9
analyzing pre-and postnatal mCpG dynamics in mouse organs, including heart, reports that 2 0 continuous loss of mCpG at enhancer regions dominates prenatal development, while gain of 2 1 mCpG is characteristic for postnatal stages. One reason for this discrepancy could be the 2 2 different developmental stage of mice and men at birth. Another reason could be a postnatal 2 3 change in cellular composition. In case of the heart, fetal and infantile heart predominantly 2 4 consist of CMs. After birth CMs loose cell cycle activity. In contrast, endothelial and 2 5 mesenchymal cell proliferation augments after birth 15 . This results in an approximately 50% 2 6 lower proportion of CM nuclei in adult as compared to prenatal mouse 12 and human hearts (Fig.  2  7 1c). The resulting increasing postnatal cellular complexity may mask cell type-specific low 2 8 methylated regions leading to the predominant detection of a gain of methylation in tissues after 2 9
birth. 3 0
The interplay of epigenetic signatures and gene expression that we observed during 3 2 development was not evident in chronic heart failure. Only six genes showed differential mCpG 3 3
at their gene body between non-failing and failing CMs. Of those, none showed a statistically 3 4 significant differential expression. Also LMRs with cis-regulatory properties showed a very low 3 5 degree of disease-associated mCpG changes. Strikingly, these alterations were not associated 1 with an altered chromatin state and were not found near to differentially expressed genes. Thus, 2 mCpG remains relatively stable in chronic heart failure. 3 4
However, pathological gene expression in failing CMs was significantly linked with levels of 5 active histone marks. These data are consistent with recent observations on the role of 6 bromodomain proteins in the heart, which recognize acetylated histones 45, 46 . Blockade of the 7 bromodomain protein Brd4 by small molecule compounds inhibited pathological gene 8 expression and progression of heart disease in a mouse model of cardiac pressure overload and 9
in CMs in vitro 45, 46 . A recent series of publications 47-49 reports a regulatory role of the histone 1 0 mark H3K9me2, a mark not studied in this project. Future studies are necessary to show 1 1
whether the proposed mechanisms are implicated in human heart failure. 1 2 1 3
Genome-wide association studies for multiple diseases have identified a plethora of disease-1 4
associated variants in the non-coding genome 50,51 . Many of these genetic variants were mapped 1 5
to loci with regulatory properties, including enhancers 52 . Recent comprehensive studies have 1 6 generated genome-wide enhancer maps of heart tissue and have linked specific enhancer 1 7
regions with genetic variants associated with myocardial repolarization and conduction 29 and 1 8
other forms of cardiac disease 23 . However, these studies do not address in which cardiac cell 1 9
type and developmental or disease state disease-associated enhancers exist. The present study 2 0 identified > 100,000 LMRs with cis-regulatory signatures. Genetic variants which have previously 2 1 been linked with cardiac arrhythmia, coronary or congenital heart disease were enriched in 2 2 these regions in CMs. Notably, SNP-bearing LMRs were strongly associated with genes, which 2 3
have previously been identified in genetic forms of cardiac channelopathies, including 2 4 pacemaker channels (HCN4 -Brugada syndrome), multiple K + channels (KCNE1, KCNH2, 2 5 KCNJ2, KCNQ1 -long and short QT syndromes) and voltage-gated Na + channels (SCN5A -2 6
Brugada syndrome, sick sinus syndrome) 53 . Further studies are needed to directly link 2 7 enhancers containing genetic variants with CM genes. 2 8 2 9
The present study identifies mCpG and histone modifications as connected or separate layers of 3 0 epigenetic regulation during human CM development and disease, respectively. This detailed 3 1
insight into the CM epigenome in intact human hearts will be important for several areas of 3 2 research. First, this CM epigenome may serve as a roadmap for further studies in ES or iPS 3 3 cells to generate mature CMs in vitro for cell therapy of heart disease and for direct 3 4
reprogramming of cells into CM in vivo. Second, our epigenetic data enable functional 3 5 annotation of non-coding regions of the genome in CMs. This will be important to unravel the 1 genetics of cardiac disease in non-coding regions of the genome. Further epigenetic studies of 2 other cardiac cell types will help to better understand the contribution of individual cell types to 3 cardiac disease. Third, this CM epigenome provides comprehensive insight into the molecular 4 marks which are associated with physiological and pathological gene expression in CMs. Future 5 studies mapping the three-dimensional architecture, protein complexes and non-coding RNAs 6 will help to develop new strategies for treatment of heart disease. 7
METHODS
2
Human cardiac biopsies 3
Left ventricular biopsies from male hearts were used for cardiac myocyte nuclei isolation. These 4 investigations were approved by the ethics committees of the Mount Sinai School of Medicine (New York, 5 USA) and the Universities of Freiburg, Jena and Munich (Germany) (Suppl. Table 1 ). All samples retrieved 6 during interventions (fetal and failing as well as rejected donor hearts) were immediately flash frozen and 7 stored at -40 to -80°C. Tissue from accidentally killed patients was flash frozen during the autopsy not later 8 than 24h after death. To comply with the ethics committee approval, we unassigned patient information and 9 genomic sequence information (Supplementary Table 1 and 2). 1 0 1 1 FACS of cardiac myocyte nuclei 1 2
All steps were performed at 4 °C to ensure integrity of chromatin and RNA. For nuclear RNA 1 3
isolation RNAsin (80 U/ml, Promega) was added to all buffers. Isolated nuclei were stained in 1 4 500 µl staining buffer (phosphate buffered saline (PBS) containing 1 % bovine serum albumin 1 5
(BSA), 22.5 mg/ml glycine, 0.1% Tween 20) using anti-PCM1 (1:500, HPA023370, Sigma) 1 6
and/or anti-PLN antibodies (1:500, A010-14, Badrilla) for 30 minutes. For isotype control 1 7
stainings we used primary antibodies lacking target specificity (1:1000, anti-mouse, 554121, BD; 1 8
1:1000, anti-rabbit, Z25308, Life technologies). Subsequently, the corresponding Alexa488-1 9
and/or Alexa568-labeled secondary antibodies (1:1000, A11029 and A11011, Invitrogen) were 2 0 added. After 30 minutes of incubation, nuclei were pelleted by centrifugation (1000 x g, 5 2 1 minutes) and resuspended in 1 ml PBS containing 1 mM ethylenediaminetetraacetic acid 2 2 (EDTA). Nuclei were filtered (CellTrics 30 µm, Sysmex) and incubated with Draq7 (final 2 3 concentration 2.25 nM, Cell Signaling) for 10 minutes. Nuclei were analyzed (Bio-Rad S3, Bio-2 4
Rad; LSRFortessa, BD) and sorted by flow cytometry (Bio-Rad S3, Bio-Rad). 2 5 2 6 FACS of fetal cardiac myocytes 2 7
Human fetal heart tissue was cut in small pieces and incubated in collagenase type II (1 mg/ml; 2 8
Worthington) in Hanks solution (NaCl, 136 mM; NaHCO 3 , 4.16 mM; NaPO 4 , 0.34 mM; KCl, 5.36 2 9 mM; KH 2 PO 4 , 0.44 mM; dextrose, 5.55 mM; HEPES, 5 mM) six hours at 37 °C with gentle 3 0
shaking. After incubation, cells were centrifuged (1200 rpm, 5 min) and the supernatant was 3 1
removed. BSA 1 mg/ml in PBS-Ca 2+ /Mg 2 solution was added to the cellular pellet and was 3 2 pipetted gently to dissociate the cells. After dissociation, cells were filtered and used for analysis. 3 3
Cells were stained in ice for 1 h at a concentration of 2.5 × 10 6 cells/ml with anti-SIRPA-IgG-3 4
phycoerythrin-Cy7 (clone SE5A5; BioLegend; 1:100) and anti-CD90-allophycocyanin (clone: 3 5 5E10; BD Pharmingen; 1:100). For FACS, the cells were sorted at a concentration of 10 6 1 cells/ml in PBS-Ca 2+ /Mg 2 with 10% FBS using an Aria II cell sorter (BD Biosciences). To prevent 2 cell death due to pressure and sheer stress, all sorts were performed with a 100 μ m nozzle. 3 4
Chromatin immunoprecipitation sequencing (ChIP-seq) 5
Isolated cardiac myocyte nuclei were fixed with paraformaldehyde (final concentration 1 %, 6
Thermo Fisher) for 2 minutes at room temperature. Fixation was quenched by adding glycine to 7 a final concentration of 0.125 M. Nuclei were washed twice with washing buffer (50 mM Tris-HCl 8 pH 8.0, 10 mM EDTA) supplemented with protease inhibitors (cOmplete Protease Inhibitor 9
Cocktail, Roche). After addition of sodium dodecyl sulfate (SDS) to a final concentration of 1 %, 1 0 nuclei were incubated for 10 minutes. Chromatin was sonicated using a Bioruptor (Diagenode) 1 1
with 30 cycles (30 s on/ 30 s off; high energy). After centrifugation (13000 x g, 10 min) the 1 2 chromatin containing supernatant was used for ChIP experiments. The amount of chromatin 1 3
(measured as DNA) was quantified using a Qubit 2.0 fluorometer (Life technologies) and the 1 4
corresponding Qubit dsDNA HS assay kit (Life technologies). 100-200 ng of isolated chromatin 1 5
was used for ChIP experiments. The immunoprecipitation, reversal of cross-linking and DNA 1 6
purification were performed using the ChIP-IT High Sensitivity Kit (Active Motif) following the 1 7
manufacturer's manual and the antibodies listed in Supplementary Table 5 . The eluted DNA 1 8
(200 µl) was concentrated by evaporation at room temperature using a vacuum concentrator 1 9
(Eppendorf) to 55.5 µl. Libraries were prepared using the NEBNext Ultra DNA Library Prep Kit 2 0
for Illumina (NEB) according to the manufacturer's manual omitting the size selection. Library 2 1 amplification was monitored after addition of Eva Green (Biotium) by qPCR using a real-time 2 2 PCR cycler (Stratagene) and stopped after the turning point of the amplification curve was 2 3
reached. Libraries were sequenced on Illumina sequencers in paired-end mode. WGBS-seq libraries were constructed from DNA extracted from purified nuclei as described 12 . 5
For small DNA amounts from sorted fetal cardiac myocytes a tagmentation-based protocol (T-6 WGBS) 54 was chosen. Libraries were sequenced on Illumina sequencers in paired-end mode. 7 8 5-Hydroxymethyl-cytosine sequencing (5hmC-seq) 9
DNA was extracted from sorted nuclei using the AllPrep DNA/RNA Kit (Qiagen). DNA was 1 0
sheared in a volume of 100 µl at low intensity for 30 cycles (30 sec on/ 90 sec off) using a 1 1
Bioruptor (Diagenode). Sheared DNA was processed using the hydroxymethyl Collector-Seq Kit 1 2
(Active Motif) according to manufacturer's instructions. The resulting DNA was used for library 1 3 generation using the NEBNext Ultra DNA Library Prep Kit (NEB). Libraries were sequenced on 1 4
Illumina sequencers in paired-end mode. 1 5 1 6
Gene ontology 1 7
To identify enriched GO terms in the categories "biological process", "cellular component" and 1 8
"molecular function" ClueGO 55 was used. Bonferroni step-down correction was performed for 1 9
multiple testing-controlled p-values. The GO term connectivity threshold was adjusted to 0.3 2 0 (kappa value) and only pathways with a p-value ≤ 0.01 were considered as significant. The 2 1
resulting terms were functionally grouped and illustrated, whereby the most significant term in 2 2 each group was selected as leading term. 2 3 2 4
Processing of sequencing reads and mapping 2 5
All bioinformatics tools used to analyze sequencing data were integrated in the Galaxy platform 2 6 56 . Quality and adapter trimming of sequencing reads was performed prior to mapping to remove 2 7 low quality reads and adapter contaminations. RNA-seq data were mapped to the human 2 8 genome (hg19) using Tophat2 57 . ChIP-seq and 5hmC-seq data were mapped using Bowtie2 58 2 9
and WGBS-seq using Bismark 59 . PCR duplicates were removed using SAMtools 60 . Quality and 3 0 adapter trimming of sequencing reads was performed prior to mapping to remove low quality 3 1 reads and adapter contaminations. RNA-seq data were mapped to the human genome (hg19) 3 2 using Tophat2 57 . PCR duplicates were removed using SAMtools 60 . 3 3 3 4 3 5
RNA-seq data analysis 1
Due to the high number of intronic reads arising from unspliced RNAs in nuclear RNA-seq data 2 13,61 we used intronic and exonic regions of coding genes for gene expression analysis. Mapped 3 RNA fragments were further processed using Cuffnorm 62 to calculate fragments per kilobase per 4 million fragments mapped (FPKM) values as an estimate of transcript expression. For differential 5 gene expression HTSeq count 63 and Deseq2 64 were used. A q-value of < 0.05 was considered 6 as significant. Genes with expression values of < 3 FPKM in all compared groups were excluded 7 from the differential gene expression analysis. We used Cufflinks 62 to determine the main 8 transcription start (TSS) and stop site (TES) of each coding gene using merged RNA-seq data 9 from all assessed stages. To exclude biases we analyzed alternative usage of TSS and TES 1 0 sites using Cuffdiff 62 , and did not observe significant differences between fetal, infant, adult non-1 1
failing, and adult failing cardiac myocytes. 1 2 1 3
Correlation of gene expression and epigenetic marks 1 4
For a comparison of differential gene expression with results obtained from ChIP-seq and 1 5
WGBS, genes differentially regulated in failing as compared to non-failing hearts were ranked 1 6
according to fold changes (log2(F/NF)). This ranking was applied to data obtained from ChIP-1 7 seq and WGBS. WGBS data were used to calculate differential mCpG of gUMRs and genic 1 8
regions of the ranked genes (F-NF). The ratio of ChIP-seq data (F/NF) was calculated using 1 9
bamCompare 65 . For quantification of H3K27ac, H3K9ac and H3K4me3 promoter (TSS ± 1kb) 2 0 and for H3K36me3, H3K9me3, H3K27me3 and H3K4me1 genic regions (TSS to TES) were 2 1 used. 2 2 2 3 2 4
ChIP-seq and 5hmC data analysis 2 5
Sequencing data were processed using DeepTools 65 . For comparison of different datasets, read 2 6
counts were normalized to the geometric mean of the genome-wide read count. This 2 7 normalization was performed for the different analyzed features (i.e. gUMRs, LMRs). To 2 8
combine results of different histone modifications, the normalized ratios of the individual marks 2 9
were averaged on a logarithmic scale. For visualization, we merged the results of biological 3 0
replicates. 3 1 3 2 ChrommHMM 3 3
ChromHMM 37 was used to learn a 10-state model predicting chromatin states based on ChIP-3 4 seq data from non-failing adult cardiac myocytes. For the annotation of chromatin states in 3 5 cardiac myocytes we used ChIP-seq data generated for H3K27ac, H3K9ac, H3K36me3, H3K36me3, ENCSR434MDA; H3K27ac, ENCSR150QXE; H3K4me3, ENCSR487BEW, 1 7
H3K27me3, ENCSR503YOF) generated by the Encode and Roadmap consortia 19-21 . 1 8 1 9
mCpG analysis 2 0 mCpG data were extracted from mapped reads and data of both strands were merged using 2 1
MethylDackel (https://github.com/dpryan79/MethylDackel). For segmentation using previously 2 2 described algorithms 20,21 , we merged the replicates of the different stages to increase the 2 3 coverage. In brief, genomic regions with highly disordered mCpG (partially methylated regions, 2 4 PMR) were identified using a 101 CpG sliding window with a step size of 1 CpG. A two-state 2 5
Hidden-Markov model identified PMRs based on the deviation of methylation level distributions 2 6 from the typical polarized distribution, which favors high and low methylation. Neighboring PMR 2 7 segments were fused. After masking of PMRs we smoothed the mCpG data using a running 2 8 window of 3 CpGs to reduce noise. To identify suitable parameters (minimal number of CpGs 2 9
and mCpG cut-off) for the identification of hypomethylated regions we calculated the false 3 0 discovery rate by comparing the number of identified regions in the original and a randomized 3 1 methylome. For all methylomes generated in this study at least 3 CpGs and a mCpG of ≤ 50% 3 2 was chosen as parameter for the detection of hypomethylated sites. These parameters ensured 3 3 in all assessed methylomes a FDR < 5%. We used a cut-off of 30 CpGs to discriminate low-and 3 4
un-methylated regions (LMRs < 30 CpGs, UMRs ≥ 30 CpGs) 20,21 . This cut-off clearly separated 3 5
CpG-low regions with methylation levels between 10 and 50% (LMRs) from un-methylated CpG-1 rich regions (UMRs) 20,21 . 2 3
Since the segmentation result is influenced by the local sequencing depth and surrounding 4 mCpG variability we merged the segments of the different stages using MergeBED 66 to obtain a 5 comprehensive set of cardiac myocyte LMRs, UMRs and PMRs. These regions were used for all 6 further steps. The high degree of UMRs overlapping genic regions prompted us to define genic 7
UMRs (gUMRs). Since genic demethylation is initiated at the transcription start site (TSS) and 8 progresses towards the 5' region of the gene, gUMRs overlap with the TSS. Only genes 9 spanning at least 1.5 kb outside of CpG islands were used for this assignment. Finally, CpGs 1 0
overlapping with annotated CpG islands 67 were removed to obtain gUMRs. Genes with distinct 1 1 low genic mCpG fulfilled the following criteria. They harbor a gUMR of at least 5 kb and/or the 1 2 gUMRs overlap with at least 25 % of the gene. An additional prerequisite is that the gUMRs 1 3
consist of at least 10 CpGs. Fully methylated regions (FMRs) represent genomic regions not 1 4
overlapping with CpG islands, LMRs, UMRs and PMRs. 1 5 1 6
Replicate-based differential methylation analysis (replicate DMR) was performed using 1 7
Metilene 68 for FMRs, CpG islands, LMRs, gUMRs and PMRs. Since genic regions downstream 1 8
of gUMRs were frequently partially methylated, too, PMRs overlapping a single gene to at least 1 9
75% were removed from differential methylation analysis. For the analysis of differential mCpG 2 0
we used the results obtained from the individual biological replicates. A difference of > 10 % and 2 1 a p-value ≤ 0.001 was considered as significant. A minimal coverage of 1 in all compared 2 2 samples was required to include a CpG in the statistical analysis. Biological replicates with a 2 3 median CpG coverage of ≤ 4 were excluded from the statistical analysis. 2 4 2 5
For the identification of differentially methylated regions (DMRs) between adult heart tissue and 2 6 cardiac myocytes we used the binary segmentation algorithm implemented in Metilene 68 . For 2 7 this analysis, we used Encode data from human left ventricle and compared it with the merged 2 8
data obtained from cardiac myocyte nuclei from non-failing adult hearts. A difference of > 10 % 2 9 and a p-value ≤ 0.001 was considered as significant. DMRs spanning less than 10 CpGs were 3 0 rejected. 3 1
For visualization, we merged the results of biological replicates and smoothened the data using 3 2 a running average of three CpGs. 3 3 3 4
General bioinformatic analysis 3 5
We used Homer 69 to perform a de novo motif analysis using the "size given" option. GREAT 28 1 was used to identify genes in proximity (≤ 10 kb) to LMRs and to annotate genes within 2 regulatory domains of SNPs. DeepTools 65 and HiCExplorer 70 were used to display traces and 3 heatmaps and to perform cluster analysis. Annotations and genome files (hg19) were obtained 4 from the UCSC 71 . Prism 5 (GraphPad) was used for statistical analysis and graphs. 5 6 SNP identification 7
Disease-associated SNPs were obtained from the NHGRI-EBI GWAS catalog for different traits 8 on Sept. 30 th , 2016 72 . Search terms were: cancer, digestive system disease, immune system 9 disease, metabolic system disease, nervous system disease and hypertension. In addition, we 1 0 searched and combined loci retrieved for the search terms congenital heart and heart 1 1 malformation (combined term: congenital heart disease), myocardial infarction and coronary 1 2 heart disease (combined term: coronary heart disease) as well as heart rate, PR interval, QT 1 3 interval and cardiac arrhythmia (combined term: cardiac arrhythmia). Duplicate SNPs were 1 4 removed. SNAP 73 was used to retrieve proxy SNPs in LD (R 2 > 0.8, CEU population, 1000 1 5
Genomes, Pilot 1) 72 with the lead SNPs. 1 6 1 7
Data availability 1 8
All sequencing datasets reported in this manuscript are deposited in the Short Read Archive 1 9
(SRA) at the National Center for Biotechnology Information (NCBI) under the BioProject ID 2 0 PRJNA353755. Additional data that support the findings of this study are available from the 2 1 corresponding author upon request. 
